Cargando…

PARP Inhibitors Resistance: Mechanisms and Perspectives

SIMPLE SUMMARY: This review aims to analyze the emerging issue regarding PARP inhibitor’s resistance in tumors and their consequence on disease prognosis and treatment. Besides, we evaluate possible strategies and new therapeutic approaches to overcome PARPis resistance. ABSTRACT: PolyADP-ribose pol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giudice, Elena, Gentile, Marica, Salutari, Vanda, Ricci, Caterina, Musacchio, Lucia, Carbone, Maria Vittoria, Ghizzoni, Viola, Camarda, Floriana, Tronconi, Francesca, Nero, Camilla, Ciccarone, Francesca, Scambia, Giovanni, Lorusso, Domenica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945953/ https://www.ncbi.nlm.nih.gov/pubmed/35326571 http://dx.doi.org/10.3390/cancers14061420

Ejemplares similares

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
por: Musacchio, L., et al.
Publicado: (2022)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
por: Giustozzi, Alessandra, et al.
Publicado: (2021)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

PTEN and Gynecological Cancers
por: Nero, Camilla, et al.
Publicado: (2019)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital
por: Bizzarri, Nicolò, et al.
Publicado: (2021)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)
por: Nero, Camilla, et al.
Publicado: (2020)

One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer
por: Fanfani, Francesco, et al.
Publicado: (2018)

Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer
por: Capasso, Ilaria, et al.
Publicado: (2023)

Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis
por: Ciccarone, Francesca, et al.
Publicado: (2022)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the Literature
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Epigenetic Insights on PARP-1 Activity in Cancer Therapy
por: Pinton, Giulia, et al.
Publicado: (2022)

Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis
por: Nero, Camilla, et al.
Publicado: (2022)

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
por: Cappuccio, Serena, et al.
Publicado: (2020)

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
por: Nero, Camilla, et al.
Publicado: (2022)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
por: Banerjee, Susana, et al.
Publicado: (2020)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
por: Giudice, Elena, et al.
Publicado: (2023)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

Effectiveness and safety of a one-yearly elongation approach of growing rods in the treatment of early-onset scoliosis: A case series of 40 patients with definitive fusion
por: Vittoria, Francesca, et al.
Publicado: (2022)

Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know
por: Russo, Luca, et al.
Publicado: (2021)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)

PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment
por: D'Angeli, Floriana, et al.
Publicado: (2019)

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
por: Nero, Camilla, et al.
Publicado: (2022)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8bum5rl4oetj0hnbf97khl5paq